WO2009064034A1 - Réduction de l'aspect de la mélanine sur la peau avec un rayonnement de lumière rouge et kit de rayonnement de lumière rouge associé - Google Patents

Réduction de l'aspect de la mélanine sur la peau avec un rayonnement de lumière rouge et kit de rayonnement de lumière rouge associé Download PDF

Info

Publication number
WO2009064034A1
WO2009064034A1 PCT/KR2007/005766 KR2007005766W WO2009064034A1 WO 2009064034 A1 WO2009064034 A1 WO 2009064034A1 KR 2007005766 W KR2007005766 W KR 2007005766W WO 2009064034 A1 WO2009064034 A1 WO 2009064034A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
band radiation
acid
red narrow
red
Prior art date
Application number
PCT/KR2007/005766
Other languages
English (en)
Inventor
Seung Yoon Lee
Original Assignee
Seung Yoon Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seung Yoon Lee filed Critical Seung Yoon Lee
Priority to AU2007361011A priority Critical patent/AU2007361011A1/en
Priority to PCT/KR2007/005766 priority patent/WO2009064034A1/fr
Priority to CA2707074A priority patent/CA2707074A1/fr
Publication of WO2009064034A1 publication Critical patent/WO2009064034A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A61B18/203—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser applying laser energy to the outside of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452—Skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared

Definitions

  • a variety of topical treatment products for skin brightening are commercially available, such as topical lotions and gels containing melanin-inhibiting ingredients, along with a sunscreen.
  • melanin-inhibiting ingredients include hy- droquinone, kojic acid and arbutin.
  • melanin-inhibiting ingredients include hy- droquinone, kojic acid and arbutin.
  • the effectiveness of such topical agents varies upon skin types and the degree of pigmentation problems.
  • certain melanin- inhibiting ingredients such as mercury (II) chloride, hyroquinone and , kojic acid, are believed to have potential toxicity.
  • Other treatments for brightening skin tones include chemical or physical peels to remove the outer layer of the skin.
  • the present invention is directed to a method of reducing appearance of melanin on the skin of a subject.
  • the method comprises exposing the skin to red narrow-band radiation at a wavelength(s) in a range of between 620 nm and 750 nm and having a band width of between 0 nm and 20 nm, in an effective dose to cause the appearance of the skin melanin to diminish and essentially not to cause pho- tothermolysis of the skin.
  • the present invention is directed to a method of reducing appearance of melanin on the skin of a subject.
  • the method comprises exposing the skin to red non-coherent narrow-band radiation at a wavelength(s) in a range of between 620 nm and 750 nm and having a band width of between 0.1 nm and 20 nm, in an effective dose to cause the appearance of the skin melanin to diminish.
  • the present invention is directed to a kit that comprises a radiation source generating red narrow-band radiation at a wavelength(s) in a range of between 620 nm and 750 nm, the narrow band radiation having a band width of between 0 nm and 20 nm and having a radiation power of between 10 mW/cm and 120 mW/cm .
  • the kit further comprises a manual instructing a user how to use the red narrow-band radiation for red narrow-band irradiation treatment to reduce appearance of melanin on the skin of a subject.
  • the present invention also includes use of red narrow-band radiation at a wavelength(s) a range of between 620 nm and 750 nm and having a band width of between 0 nm and 20 nm, in an effective dose to cause the appearance of the skin melanin to diminish and not to cause photothermolysis of the skin.
  • the present invention has several advantages. For example, the reduction of the appearance of melanin on the skin of a subject can be effectively achieved in a noninvasive way.
  • a relatively non-thermal, red light-emitting diode (LED) radiation source can be employed in the invention, which provides an additional advantage that the reduction of the appearance of melanin of the skin can be effectively achieved in a non-thermal way.
  • LED radiation since LED radiation is relatively safe, patients can perform the treatment at their home. Also, microdermabrasion or exfoliating of the skin, or chemical peel can be employed prior to the red narrow-band radiation treatment.
  • the beneficial effect associated with the peel can enhance the effect of lowering the skin melanin appearance, because the peel can remove excessive stratum corneum, or exfoliate a skin surface, and generate a relatively even skin surface. As a consequence, light scattering by excessive stratum corneum can be reduced. The reduction in light scattering can in turn allow as many photons as available at a given energy density of the red narrow-band radiation can penetrate into the skin, and thus, reduction of the skin melanin appearance can be obtained more efficiently. Moreover, a thin layer of transparent water-based gel on the skin prior to the red narrow-band radiation treatment can be employed.
  • the transparent water gel layer can make a surface through which relatively large amounts of photons of the red narrow-band radiation can penetrate, and thus, reduction of the skin melanin appearance can be obtained effectively with relatively low power density and/or less duration time.
  • the thin layer of transparent water-based gel can prevent potential dehydration of the skin surface subject to the irradiation treatment and can keep the skin hydrated during the treatment.
  • application of skin- brightening cosmetics before or after the red narrow-band radiation treatment can enhance the effect of lowering the skin melanin appearance.
  • the figure is a schematic drawing showing a kit of the invention that includes a radiation device generating the red narrow-band radiation employed in the invention, and a manual instructing a user how to use the red narrow-band radiation for red narrow-band irradiation treatment to reduce the appearance of melanin on the skin of a subject.
  • the invention employs red narrow-band radiation at a wavelength(s) in a range of between 620 nm and 750 nm and having a band width of between 0 nm and 20 nm in an effective dose to cause the appearance of melanin on the skin of a subject to diminish.
  • the "appearance" of melanin on the skin of a subject is a melanin level obtained based upon the amount of beam reflected back from the skin relative to the amount of reference beam irradiated onto the skin.
  • Such amount can be measured by any suitable method known in the art, such as a MexameterTM, which is an objective skin color-measuring device, and has been reported to provide a reproducible and sensitive means of quantifying small skin color differences.
  • a Mexameter TM measures the amount of beam reflected back from the skin relative to the amount of reference beam irradiated onto the skin, and calculates a melanin level in an indicative index (e.g., when given two calculated indexes are 100 and 150; index 150 means darker skin tone than index 100).
  • index 150 means darker skin tone than index 100.
  • narrow band radiation at a wavelength(s) having a band width of 20 nm means that the radiation at the wavelength(s) has, for example, a deviation of 10 nm.
  • narrow band radiation at a wavelength(s) having a band width of 0 nm means that the radiation at the wavelength(s) has a deviation of + 0 nm.
  • a "subject” is a mammal, preferably a human. Subject and patient are used interchangeably.
  • the "effective dose” is a dose sufficient to cause statistically significant reduction, or reduction of the appearance of melanin noticeable enough for the subjects to perceive themselves, in the appearance of melanin on the skin after each dose or after a plurality of consecutive such doses.
  • the "effective dose” is a dose sufficient to cause statistically significant reduction of 1%, 5%, 10%, 15%, 20%, etc. in the melanin levels obtained by a Mexameter in the appearance of melanin on the skin after each dose or after a plurality of consecutive such doses.
  • the doses are typically repeated at intervals of from 0.5 day (twice per day) to 10 days.
  • the doses are repeated at intervals of from one day to 4 days, such as 2 days or 3 days.
  • each irradiant dose is up to 7 days apart, such as 1 day apart, 2 days apart, 3 days apart or 4 days apart. More specifically, each irradiant dose is 1 day apart, 2 days apart or 3 days apart.
  • the intervals can be the same length or different lengths. In one specific embodiment, the intervals are the same length.
  • the effective dose essentially does not cause photothermolysis of the skin.
  • Selective photothermolysis is a photothermolytic reaction by which a target chromophore is selectively damaged or destroyed by light, resulting in destruction of the target chromophore or necrosis of the cells that contain the target chromophore.
  • Photothermolysis generally occurs when the following three fundamental conditions are met:
  • Wavelength specific wavelength that can be absorbed by the target moleule
  • Pulse duration pulse duration of the pulsed light from a laser that is shorter than the thermal relaxation time of the target (TRT: TRT is the time taken for the target to dissipate about 63% of the incident thermal energy);
  • Fluence energy density, J/cm : a sufficient fluence (energy density; the amount of energy per unit area) to create the thermal damage enough to destroy the target.
  • the pulsed light from a laser when the pulsed light from a laser is absorbed by a given target within time duration shorter than the TRT of the target (thus, the pulse duration of the pulsed light should be shorter than the TRT of the target), the target cannot dissipate the heat energy to the adjacent structures before the sufficient amount of energy to destroy it accumulates in it, and therefore, is destroyed by the thermal damage.
  • the TRT of the melanosome is 0.5-1 microsecond (lO "6 second).
  • photothermolysis can occur with a laser light source that can produce short pulses.
  • the TRT is so short that only specific lasers that are equipped with a special device named Q-s witch (quality switch), which can make very high energy, ultra-short pulses in the range of nanoseconds, can induce photothermolysis of melanin pigments.
  • Q- switching which is generally also known as giant pulse formation, is a technique by which a laser can be made to produce a pulsed output beam having very short pulses. The technique allows the production of light pulses with extremely high peak power, much higher than would be produced by the same laser if it were operating in a continuous wave (constant output) mode.
  • Q- switching is generally achieved by putting a variable attenuator inside the laser's optical resonator.
  • the variable attenuator is commonly called a "Q-switch", when used for this purpose. Initially the laser medium is pumped while the Q-switch is set to prevent feedback of light into the gain medium (producing an optical resonator with low Q). This produces a population inversion, but laser operation cannot yet occur since there is no feedback from the resonator. Therefore, the amount of energy stored in the gain medium increases as the medium is pumped.
  • the stored energy will reach some maximum level; the medium is said to be gain saturated, the Q- switch device is quickly changed from low to high Q, allowing feedback and the process of optical amplification by stimulated emission to begin.
  • the intensity of light in the laser resonator builds up very quickly; this also causes the energy stored in the medium to be depleted almost as quickly.
  • the net result is a short pulse of light output from the laser, known as a giant pulse, which may have a very high peak intensity.
  • a fluence that causes photothermolysis varies depending upon the types of the target, TRT of the target, depth of the target, type of lasers, skin phototypes of the subjects, and many other things, because, at least in part, power sufficient for photothermolysis varies depending upon the target, laser type, depth of the target, skin phototypes, etc.
  • the TRT of a given melanin particle is 1 microsecond (10 " )
  • the sufficient energy density is 2 J/cm
  • the required power density is 2 J/cm divided by 10 seconds, which yields 2,000,000 watts/cm .
  • This power density generally cannot be produced with an LED light source or with a laser source unequipped with a Q-switch.
  • selective photothermolysis of melanin pigments generally does not occur.
  • the red narrow-band radiation employed in the invention does not meet at least one of the above-mentioned three requirements for photothermolysis.
  • the red narrow-band radiation employed in the invention is generated from an LED light source or a low level laser without Q switching (e.g., a low level laser unequipped with a Q switch; or a low level laser equipped with a Q switch, but without using a Q switch).
  • a low level laser without Q switching e.g., a low level laser unequipped with a Q switch; or a low level laser equipped with a Q switch, but without using a Q switch.
  • the skin of the subject is exposed to a plurality of exposures.
  • the exposures can be repeated for any time period, as long as the subject does not experience any side effect, such as photosensitity.
  • the plurality of exposures are collectively referred to as a "treatment period.”
  • the treatment period can be between one week and 12 weeks, or between two weeks and 8 weeks, such as two, three, four, five or six weeks. Alternatively, the treatment period can be longer than 12 weeks.
  • the skin is exposed to the red narrow-band radiation one, two, three, four, five, six or seven times per week during the treatment period. In another embodiment, the skin is exposed to the red narrow-band radiation four, five, six or seven times per week during the treatment period. In yet another embodiment, the skin exposure to narrow band radiation during the treatment period is only limited to the red narrow-band radiation at a wavelength(s) in a range of between 620 nm and 750 nm and having a band width of between 0 nm and 20 nm.
  • the exposures are performed other than three times a week for three week.
  • exposure of the skin to narrow band radiation at a wavelength(s) outside of the range between 620 nm and 750 nm, up to a week prior to the beginning of treatment period and after the end of treatment period, is with an energy density less than 1 J/cm .
  • exposure of the skin to narrow band radiation at a wavelength(s) greater than 750 nm, up to a week prior to the beginning of treatment period and after the end of treatment period, is in an amount less than 1 J/cm .
  • exposure of the skin to narrow band radiation at a wavelength(s) outside of the range between 620 nm and 750 nm is with an energy density of less than 1 J/cm .
  • exposure of the skin to narrow band radiation at a wavelength(s) greater than 750 nm is in an amount less than 1 J/cm .
  • the skin exposed to the red narrow-band radiation is skin from other than the face of the subject, such as the neck, the shoulder, the arms, etc.
  • the skin exposed to the red narrow-band radiation is essentially free of wrinkles.
  • an effective dose of the red narrow-band radiation depends, in each case, upon several factors, e.g., the skin types (especially skin phototypes), age, gender and condition of the subject to be treated, among others.
  • the exposure time and/or power density of the red narrow-band radiation is adjusted according to the subject's skin conditions, particularly the skin phototype of the subject. For example, individual subjects' skin phototypes, conditions, and sensitivity or reactions to light can be different from each other. Skin phototypes of subjects to be treated can be classified by the Fitzpatrick skin phototype scale shown below:
  • the Fitzpatrick 1 classification of skin phototypes of a given subject can influence the degree of absorption of the photons by the skin cells, and therefore, the degree of effect of lowering skin melanin appearance.
  • exposure time and/or radiation power of the red narrow-band radiation is increased as the skin phototype of the subject varies from skin phototype I to skin phototype VI of the Fitzpatrick's classification of skin phototypes.
  • the red narrow-band radiation treatment is employed in combination with one or more peeling means, such as superficial peeling means, known in the art.
  • At least one of microdermabrasion, exfoliating and chemical peel of the skin of the subject is performed prior to the skin exposure to the red narrow-band radiation.
  • Suitable peeling means include physical means for microdermabrasion, physical means for exfoliating of the skin surface, and chemical peeling means.
  • superficial peels remove part or all of the epidermis, which is then followed by the natural wound healing process.
  • very light superficial peels generally involve to the level of the stratum spinosum
  • light superficial peels generally involve the entire epidermis.
  • medium depth peels involve the entire epidermis plus the papillary dermis to the level of the upper reticular dermis.
  • microdermabrasion, exfoliationg or chemical peel of the skin of the subject can be performed by any suitable method known in the art.
  • Specific examples include diamond peels, crystal peels, skin scrubbers with ultrasonic waves, an exfoliating means (e.g., washable cream including fruit seeds or buffing beads), physical means of superficial skin resurfacing, and chemical peels.
  • Microdermabrasion is a cosmetic procedure in which the stratum corneum (dead outermost surface of the skin) is partially or completely removed by light abrasion, such as mechanical abrasion using jets of zinc oxide or aluminum oxide crystals, fine organic particles, or a roughened surface.
  • superficial skin resurfacing includes laser superficial resurfacing.
  • Chemical peels can be done with a composition comprising a pharmaceutically acceptable peeling agent(s), such as salicylic acid or gly colic acid.
  • the composition comprises trichloroacetic acid, resorcinol, salicylic acid, lactic acid, an alpha-hydroxy acid, a beta-hydroxy acid and a seaweed extract including an enzymatic exfoliating agent.
  • alpha-hydroxy acids include lactic acid, glycolic acid, malic acid, citric acid and tartaric acid.
  • beta-hydroxy acids include salicylic acid, benzoic acid and buteric acid.
  • chemical peel compositions comprises 10-20% trichloroacetic acid, alpha-hydroxy acid, beta- hydroxy acid and tretinoin.
  • Another example of chemical peel compositions comprises 20-30% trichloroacetic acid, Jessner's solution, a modified Jessner's solution and glycolic acid.
  • Jessner's solutions includes resorcinol, salicylic acid, 85% lactic acid and 95% ethanol. Modified Jessner's solution including these ingredients with other concentrations can also be employed.
  • Additional examples of chemical peel compositions include fruit extracts containing alpha-hydroxy acid, food extracts containing alpha- hydroxy acids, and plant extracts containing alpha-hydroxy acids or beta-hydroxy acids.
  • a chemical peel is employed in the invention.
  • suitable chemical peeling agents are as described in the previous paragraph.
  • a layer of a gel, cream or lotion is applied on the skin prior to the skin exposure to the red narrow-band radiation.
  • the skin is exposed to the red-narrow band radiation through the gel, cream or lotion layer.
  • the gel, cream or lotion has at least 70% transparency at the red narrow-band radiation. More specifically, the gel, cream or lotion has at least 90% transparency at the red narrow-band radiation.
  • a layer of a transparent gel having, for example, at least 70% transparency, particularly at least 90% transparency, at the red narrow-band radiation is applied to the skin prior to the skin exposure to the red narrow-band radiation.
  • the transparent gel is water-based. More specifically, the water-based transparent gel comprises hyaluronic acid. Even more specifically, the water-based transparent gel consists essentially of water and hyaluronic acid.
  • the red narrow-band radiation treatment is performed in combination with one or more skin-brightening cosmetic products, prior to, and/or after, the skin exposure to the red narrow band radiation.
  • Any suitable brightening cosmetic product that includes one or more skin-brightening agents known in the art can be employed in the invention.
  • Suitable skin-brightening agents include an alpha-hydroxy acid or a beta-hydroxy acid.
  • Other specific examples of suitable skin-brightening agents include hydroquinone, kojic acid, azelaic acid, licorice P-T, arbutin, melawhite, ascorb ic acid, vitamin C, magnesium-L-ascorbyl-2-phosphate and corticosteroid.
  • Specific examples of the alpha-hydroxy acids and beta-hydroxy acids are as described above. Generally, the concentrations of alpha-hydroxy acids and beta-hydroxy acids in the cosmetic compositions are relatively low compared to those of chemical peel compositions. In some more specific embodiments, the cosmetic products do not comprise retinoic acid or retinoic acid derivatives.
  • retinoic acid or retinoic acid derivatives can induce photosensitivity, causing skin irritation when exposed to light.
  • cosmetic products including retinoic acid or retinoic acid derivatives after the red narrow-band radiation treatment is not essentially limited.
  • the red narrow-band radiation is at a wavelength(s) in a range of between 620 nm and 750 nm. In any one of the embodiments described above, alternatively, the red narrow-band radiation is at a wavelength(s) in a range of between 625 nm and 700 nm. Alternatively, the red narrow-band radiation is at a wavelength(s) in a range of between 625 nm and 680 nm in any one of the embodiments described above. Alternatively, the red narrow-band radiation is at a wavelength(s) in a range of between 625 nm and 650 nm in any one of the embodiments described above.
  • the red narrow-band radiation is at a wavelength(s) in a range of between 627 nm and 639 nm in any one of the embodiments described above. More specifically, the red narrow-band radiation is at 633 nm in any one of the embodiments described above.
  • the red narrow-band radiation has a band width of between 0 nm and 20 nm.
  • the band width of the red narrow band radiation is between 0 nm and 15 nm, such as 0 nm, 6 nm, 10 nm, 12 nm or 15 nm. More specifically, in any one of the embodiments described in the previous paragraph, the band width of the red narrow band radiation is between 0 nm and 12 nm.
  • the band width of the red narrow band radiation is between 0.1 nm and 12 nm.
  • the band width of the red narrow band radiation is between 0.1 nm and 1 nm.
  • the red narrow-band radiation has power density in a range of between 10 mW/cm and 120 mW/cm . More specifically, the power density is in a range of between 10 mW/cm and 75 mW/cm in any one of the embodiments described in the two previous paragraphs. Even more specifically, the power density is in a range of between 10 mW/cm 2 and 50 mW/cm 2 in any one of the embodiments described in the two previous paragraphs.
  • the red narrow-band radiation has energy density in a range of between 10 J/cm and 200 J/cm . More specifically, the energy density is in a range of between 10 J/cm 2 and 120 J/cm 2 .
  • the energy density is in a range of between 10 J/cm 2 and 120 J/cm 2 .
  • energy density is in a range of between 10 J/cm and 100 J/cm .
  • the energy density is in a range of between 10 J/cm 2 and 70 J/cm 2 .
  • the energy density is in a range of between 10 J/cm and 75 J/cm , or between 35 J/cm and 75 J/cm .
  • the skin exposure to the red narrow-band radiation per each dose can last for any suitable time period as long as it can cause the appearance of melanin on the skin to diminish after each dose or after a plurality of such doses, and essentially not to cause photothermolysis of the skin.
  • the skin exposure to the red narrow-band radiation per each dose lasts for less than 20 minutes. More specifically, in any one of the embodiments described above, the duration of the skin exposure to the red narrow-band radiation per each dose is between 5 minutes and 20 minutes, or between 5 minutes and 15 minutes, such as 10 minutes. Alternatively, in any one of the embodiments described above, the skin exposure to the red narrow-band radiation per each dose can last for more than 20 minutes, for example, between 20 minutes and 60 minutes or between 20 minutes and 40 minutes.
  • the duration of the skin exposure to the red narrow-band radiation per each dose can last for more than 20 minutes, for example, can be in a range of between 10 minutes and 60 minutes or between 10 minutes and 30 minutes.
  • the red narrow band radiation employed in the invention any suitable radiation source can be employed, including relatively low-power laser and light-emitting diodes (LEDs) known in the art.
  • the red narrow-band radiation employed in the invention is non-coherent radiation. More specifically, the red narrow-band radiation employed in the invention is generated by a red LED device.
  • the subject to be treated has any contraindication (absolute and relative), such as photosensitive condition, especially in regards to any possibility of photosensitivity.
  • contraindication absolute and relative
  • examples of absolute contraindication include: recent history (within one weak) of systemic or topical photodynamic therapy involving any photosensitizer that has the peak absorption within the range of red light waveband (e.g. 5-aminolevulinic acid, methyl-5-aminolevulinic acid) and the use of such photosensitizer for any other purposes.
  • relative contraindication include: any photosensitive condition, such as disease (e.g.
  • porphyria erythropoietic porphyria, erythropoietic protoporphyria, porphyria cutanea tarda, variegate porphyria, hereditary coproporphyria, hepatoerythropoietic porphyria), polymorphous light eruption, hydroa vacciniforme, and other conditions that can cause photosensitivity
  • drugs e.g.
  • tetracycline fluoroquinolones, ibuprofen, amiodarone, phenothiazine, furosemide, hydrochlorothiazide, retinoic acid, isotretinoin, etc.
  • certain neurologic diseases that can be aggravated by light stimuli (certain types of epilepsy or other seizure disorders). For example, it is generally checked whether or not the subject to be treated has photosensitive condition, especially in regards to any possibility of photosensitivity, such as disease (e.g.
  • porphyria erythropoietic porphyria, erythropoietic protoporphyria, porphyria cutanea tarda, variegate porphyria, hereditary coproporphyria, hepatoerythropoietic porphyria), polymorphous light eruption, hydroa vacciniforme, and other conditions that can cause photosensitivity
  • drugs e.g.
  • the invention also includes a kit comprising a radiation source generating the red narrow-band radiation employed in the red narrow-band radiation methods described above.
  • the red narrow-band radiation has power density in a range of between 10 mW/cm and 120 mW/cm . More specifically, the power density is between 10 mW/cm and 75 mW/cm . Even more specifically, the power density is between 10 mW/cm 2 and 50 mW/cm 2 .
  • the kit further comprises a manual instructing a user how to use the red narrow-band radiation for the red narrow-band irradiation treatment to reduce appearance of melanin on the skin of a subject.
  • Features, including specific features, of the red narrow-band irradiation treatment using the kit are as described above for the methods of the invention.
  • the figure shows one embodiment of a kit of the invention, comprising a radiation device, such as an LED device, and a manual instructing a user how to use the red narrow-band radiation for the red narrow-band irradiation treatment to reduce appearance of melanin on the skin of a subject.
  • a radiation device such as an LED device
  • the housing of the radiation device of the figure can include any suitable radiation source, such as one or more red LEDs.
  • the radiation source is an LED light source or a low level laser without Q switching (e.g., a low level laser unequipped with a Q switch; or a low level laser equipped with a Q switch, but without using a Q switch).
  • the radiation source is a non-coherent radiation source, such as an LED device that includes one or more LEDs, preferably red LEDs.
  • the manual included in a kit of the invention further comprises instructions about distance between the skin of the subject and the radiation source during the red narrow-band radiation treatment, duration time per single treatment of the red narrow-band radiation and frequency of the red narrow-band radiation treatment, and warning about contraindication (absolute and relative) of the red narrow-band radiation treatment.
  • absolute and relative contraindication are as described above.
  • the warning about the contraindication of the red narrow-band radiation treatment recommends users or subjects that they should seek professional advice as to whether the subject(s) to be treated has any photosensitive condition prior to using the kit for the red narrowband radiation treatment, if they do not have prior knowledge about this.
  • the warning includes a statement that users or subjects should seek special consults advice in regards to any possibility of photosensitivity, such as disease (e.g. systemic lupus erythematosus, certain types of porphyria (erythropoietic porphyria, erythropoietic protoporphyria, porphyria cutanea tarda, variegate porphyria, hereditary coproporphyria, hepatoerythropoietic porphyria), polymorphous light eruption, hydroa vacciniforme, and other conditions that can cause photosensitivity), drags (e.g.
  • disease e.g. systemic lupus erythematosus, certain types of porphyria (erythropoietic porphyria, erythropoietic protoporphyria, porphyria cutanea tarda, variegate porphyria, hereditary coproporphyria, hepat
  • the manual further includes a chart of skin phototypes classification (e.g., the Fitzpatrick' classification of skin phototypes), and instructions about how to adjust exposure time and/or power density of the red narrowband radiation according to the skin phototypes.
  • a chart of skin phototypes classification e.g., the Fitzpatrick' classification of skin phototypes
  • the kit further comprises one or more peeling means, and/or a gel, cream, or lotion having at least 70% transparency at the red narrow-band radiation.
  • suitable peeling means and transparent gels, creams or lotions are as described above for the methods of the invention.
  • the gel, cream or lotion included in the kit has at least 90% transparency at the red narrowband radiation. More specifically, a transparent gel having at least 70% transparency, particularly at least 90% transparency, at the red narrow-band radiation is employed. Even more specifically, a water-based transparent gel having at least 70% transparency, particularly at least 90% transparency, at the red narrow-band radiation is employed.
  • the kit further comprises a skin-brightening cosmetic product that includes one or more skin-brightening agents.
  • skin-brightening agents are as described above for the methods of the invention.
  • the kit further comprises one or more peeling means, and/or a gel, cream, or lotion having at least 70% transparency at the red narrow-band radiation, and further comprises one or more skin-brightening cosmetic products.
  • the kit further comprises a pair of goggles that are specifically designed to protect the retinae of the eyes of the subject to be treated with the red narrow-band radiation from direct illumination at the wavelength(s) of the red narrow-band radiation.
  • the goggles have color and/or optical density to essentially block light at the wavelength(s) of the red narrow-band radiation.
  • the kit further comprises a device that measures the melanin level of the skin. Any suitable device that can measure a melanin level of the skin, based upon the amount of beam reflected back from the skin relative to the amount of reference beam irradiated onto the skin, can be employed in the invention, such as a Mexameter .
  • the kit is portable. More preferably, the kit is a home- therapy kit so that a user is the subject to be treated with the red narrow-band radiation.
  • the radiation source is an LED device that includes one or more LEDs, preferably red LEDs.
  • the LED device generates the red narrow-band radiation having power density in a range of between 10 mW/cm 2 and 75 mW/cm 2 , or between 10 mW/cm and 50 mW/cm .
  • Example 1 Skin Melanin Level Lowering Effects of Red Light LED Irradiation:
  • the phototherapy systemused as the light source for this study consisted of a base and interchangeable heads emitting quasimonochromatic light of each different preset wavelength from adjustable planar arrays of LEDs. Red and Blue wavebands were employed in this study.
  • the head emitting red light (Omnilux revive Photo Therapeutics Ltd., Fazeley, UK) comprised four articulated panels containing 420 LEDs each, so that they could be adjusted to fit the contour of the patient s face optimally.
  • the blue light head (Omnilux blueTM Photo Therapeutics Ltd., Fazeley, UK) consisted of five panels containing 260 LEDs each arranged in the same way.
  • the treatment heads delivered symmetrical peak wavelengths; 415 +5 nm for theblue light and 633 ⁇ 6 nm for thered light.
  • the irradiance was 40 mW/cm for theblue light and 80 mW/cm for thered light at a distance of 1 to 10 centimeters from the light source.
  • the radiant fluences, or doses, during a single treatment for twenty minutes were 48 J/ cm and 96 J/cm for theblue and red treatment heads, respectively.
  • the instrumental measurements were done in the same way as before treatment, which signaled the end of one treatment session.
  • the therapy was performed twice a week for four weeks and a three to four days interval between each session, with the 415 nm blue treatment head being used for the first treatment session followed by the 633 nm red treatment head for the second session each week.
  • the moisture level, the sebum level, and the melanin level were measured in numerical values using a Corneometer (Courage+Khazaka, KoIn, Germany), a Sebumeter (Courage+Khazaka), and a Mexameter (Courage+Khazaka), respectively.
  • the measurements before treatment were carried out after al5 minutes stabilizing period to exclude any possible influences of outdoor activity on the skin condition, e.g. by sweating or flushing.
  • the same part of the right malar area was chosen for the measurement every time to exclude any site- variation bias.
  • the measurements were pe rformed repeatedly at ten minutes after the end of treatment to exclude anypossible effects of mild heat from the phototherapy device on the measured values.
  • the phototherapy system used as the light source for this study consisted of a base and interchangeable heads emitting quasimonochromatic light of each different preset wavelength from adjustable planar arrays of LEDs. Red light and infrared light were used either alone or in combination according to each treatment protocol of the four arms of the study (see the 'Study design').
  • the near infrared head (Omnilux plus Photo Therapeutics Ltd., Fazeley, UK) comprised five articulated panels containing 108 LEDs each, so that they could be adjusted to fit the contour of the patient's face optimally.
  • the red light head (Omnilux revive Photo Therapeutics Ltd.) consisted of four panels containing 420 LEDs each arranged in the same way.
  • the treatment heads delivered symmetrical peak wavelengths; 830+5 nm for the infrared light and 633+6 nm for the red light.
  • the irradiance was 55 mW/cm for the infrared light and 105 mW/cm 2 for the red light at a distance of 1 to 10 centimeters from the light source.
  • Group 1 was treated with the 830 nm head alone, group 2 with the 633 nm head alone, group 3 with a combination of the 830 and 633 nm heads by alternating them in that order, and group 4 with a sham treatment light as the control group.
  • the standby mode of the 633 nm LED head was used as the sham treatment.
  • This study employed the split-face model; in all groups, the patients were treated only on the right half of the face with the left half being occluded.
  • the melanin level was measured by Mexameter (Courage+Khazaka, KoIn, Germany) before treatment at every treatment session. After the measurement, each patient washed his/her face and was treated for twenty minutes in the supine position with the wavelength of light as set by the protocol of his/her group. The distance between the irradiating head and the patient's nose was about 3-5 cm. In group 3, we alternated sessions of the 830 nm and 633 nm LED treatment in succession, with the 830 nm treatment head being used first. Goggles were worn to protect the retinae from direct illumination.
  • the melanin level was measured by Mexameter (Courage+Khazaka, KoIn, Germany) before treatment at every treatment session on both the exposed and the covered side of the facial skin of a given subject.
  • the same area of each malar aspect was chosen for the measurements to avoid any site-variation bias.
  • Mexameter quantifies melanin pigmentation by comparing the amount of reflected light to that of a device- generated reference beam, morphological changes in the epidermis and even in the dermis may alter this reflected beam and cause a decrease in the measured levels without any actual decrease in the total melanin amount.
  • any changes that alter the reflection of the light can affect the perceived appearance of the object. It is hypothesized that the reduction of the melanin levels measured by the Mexamter, or brightening of the skin tone (complexion) perceived by the subjects eyes, might be caused by some optical alterations of the reflected light from the skin surface.

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiation-Therapy Devices (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne un procédé permettant de réduire l'aspect de la mélanine sur la peau d'un sujet. Ledit procédé comprend l'exposition de la peau à un rayonnement de bande étroite de rouge à une ou des longueurs d'onde comprises entre 620 nm et 750 nm et ayant une largeur de bande comprise entre 0 nm et 20 nm, en dose efficace pour provoquer la réduction de l'aspect de la mélanine de la peau sans provoquer une photothermolyse sensible de la peau. En variante, l'invention concerne un procédé de réduction de l'aspect de la mélanine sur la peau d'un patient comprenant l'exposition de la peau à un rayonnement de bande étroite de rouge non cohérent à une ou des longueurs d'onde comprises entre 620 nm et 750 nm et ayant une largeur comprise entre 0,1 nm et 20 nm, en dose efficace pour provoquer la réduction de l'aspect de la mélanine de la peau. Un kit portable pour ledit procédé comprend une source de rayonnement produisant un rayonnement de bande étroite de rouge à une ou des longueurs d'onde comprises entre 620 nm et 750 nm, le rayonnement de bande étroite ayant une largeur de bande comprise entre 0 nm et 20 nm et ayant une densité de puissance comprise entre 10 mW/cm et 120 mW/cm, et un manuel indiquant à l'utilisateur comment utiliser le rayonnement de bande étroite de rouge pour le traitement par rayonnement de bande étroite de rouge pour réduire l'aspect de la mélanine sur la peau d'un sujet.
PCT/KR2007/005766 2007-11-16 2007-11-16 Réduction de l'aspect de la mélanine sur la peau avec un rayonnement de lumière rouge et kit de rayonnement de lumière rouge associé WO2009064034A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2007361011A AU2007361011A1 (en) 2007-11-16 2007-11-16 Lowering skin melanin appearance with red light radiation and red light radiation kit therefor
PCT/KR2007/005766 WO2009064034A1 (fr) 2007-11-16 2007-11-16 Réduction de l'aspect de la mélanine sur la peau avec un rayonnement de lumière rouge et kit de rayonnement de lumière rouge associé
CA2707074A CA2707074A1 (fr) 2007-11-16 2007-11-16 Reduction de l'aspect de la melanine sur la peau avec un rayonnement de lumiere rouge et kit de rayonnement de lumiere rouge associe

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2007/005766 WO2009064034A1 (fr) 2007-11-16 2007-11-16 Réduction de l'aspect de la mélanine sur la peau avec un rayonnement de lumière rouge et kit de rayonnement de lumière rouge associé

Publications (1)

Publication Number Publication Date
WO2009064034A1 true WO2009064034A1 (fr) 2009-05-22

Family

ID=40638866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/005766 WO2009064034A1 (fr) 2007-11-16 2007-11-16 Réduction de l'aspect de la mélanine sur la peau avec un rayonnement de lumière rouge et kit de rayonnement de lumière rouge associé

Country Status (3)

Country Link
AU (1) AU2007361011A1 (fr)
CA (1) CA2707074A1 (fr)
WO (1) WO2009064034A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012011042A3 (fr) * 2010-07-22 2012-03-22 Koninklijke Philips Electronics N.V. Améliorations en photothérapie
WO2012011013A3 (fr) * 2010-07-22 2012-03-22 Koninklijke Philips Electronics N.V. Améliorations relatives à la photothérapie
WO2012010996A3 (fr) * 2010-07-22 2012-03-22 Koninklijke Philips Electronics N.V. Améliorations apportées à la photothérapie
US8651112B2 (en) 1998-11-30 2014-02-18 David McDaniel Process for treatment of psoriasis
US8651111B2 (en) 2003-04-10 2014-02-18 David H. McDaniel Photomodulation methods and devices for regulating cell proliferation and gene expression
US9017391B2 (en) 1998-11-30 2015-04-28 L'oreal Method and apparatus for skin treatment
US9144690B2 (en) 2003-07-31 2015-09-29 L'oreal System and method for the photodynamic treatment of burns, wounds, and related skin disorders
US9192780B2 (en) 1998-11-30 2015-11-24 L'oreal Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders
US9227082B2 (en) 1998-11-30 2016-01-05 L'oreal Method and apparatus for acne treatment using low intensity light therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004499A1 (en) * 2000-01-13 2003-01-02 Mcdaniel David H. Method and apparatus for the photomodulation of living cells
US20050197681A1 (en) * 2004-02-06 2005-09-08 Lumiphase Inc. Method and device for the treatment of mammalian tissues
US20050246997A1 (en) * 2004-04-09 2005-11-10 Bishop Robert P Removable tie-down clip and method of making same
WO2007044840A2 (fr) * 2005-10-10 2007-04-19 Reliant Technologies, Inc. Élimination de contenu transépidermique induite par laser par photothermolyse fractionnelle
US20070198003A1 (en) * 2005-12-23 2007-08-23 Yacov Domankevitz Treating dermatological conditions using an alexandrite laser

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004499A1 (en) * 2000-01-13 2003-01-02 Mcdaniel David H. Method and apparatus for the photomodulation of living cells
US20050197681A1 (en) * 2004-02-06 2005-09-08 Lumiphase Inc. Method and device for the treatment of mammalian tissues
US20050246997A1 (en) * 2004-04-09 2005-11-10 Bishop Robert P Removable tie-down clip and method of making same
WO2007044840A2 (fr) * 2005-10-10 2007-04-19 Reliant Technologies, Inc. Élimination de contenu transépidermique induite par laser par photothermolyse fractionnelle
US20070198003A1 (en) * 2005-12-23 2007-08-23 Yacov Domankevitz Treating dermatological conditions using an alexandrite laser

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8651112B2 (en) 1998-11-30 2014-02-18 David McDaniel Process for treatment of psoriasis
US9017391B2 (en) 1998-11-30 2015-04-28 L'oreal Method and apparatus for skin treatment
US9192780B2 (en) 1998-11-30 2015-11-24 L'oreal Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders
US9227082B2 (en) 1998-11-30 2016-01-05 L'oreal Method and apparatus for acne treatment using low intensity light therapy
US9814906B2 (en) 1998-11-30 2017-11-14 L'oreal Method and apparatus for skin treatment
US8651111B2 (en) 2003-04-10 2014-02-18 David H. McDaniel Photomodulation methods and devices for regulating cell proliferation and gene expression
US9144690B2 (en) 2003-07-31 2015-09-29 L'oreal System and method for the photodynamic treatment of burns, wounds, and related skin disorders
WO2012011042A3 (fr) * 2010-07-22 2012-03-22 Koninklijke Philips Electronics N.V. Améliorations en photothérapie
WO2012011013A3 (fr) * 2010-07-22 2012-03-22 Koninklijke Philips Electronics N.V. Améliorations relatives à la photothérapie
WO2012010996A3 (fr) * 2010-07-22 2012-03-22 Koninklijke Philips Electronics N.V. Améliorations apportées à la photothérapie

Also Published As

Publication number Publication date
AU2007361011A1 (en) 2009-05-22
CA2707074A1 (fr) 2009-05-22

Similar Documents

Publication Publication Date Title
US20090177190A1 (en) Lowering skin melanin appearance with red light radiation and red light radiation kit therefor
Dierickx et al. Visible light treatment of photoaging
Weiss et al. Clinical trial of a novel non‐thermal LED array for reversal of photoaging: Clinical, histologic, and surface profilometric results
WO2009064034A1 (fr) Réduction de l'aspect de la mélanine sur la peau avec un rayonnement de lumière rouge et kit de rayonnement de lumière rouge associé
Weiss et al. Treatment of poikiloderma of Civatte with an intense pulsed light source
Goldman et al. Intense pulsed light as a nonablative approach to photoaging
Liew Laser hair removal: guidelines for management
DeHoratius et al. Nonablative tissue remodeling and photorejuvenation
Munavalli et al. Photoaging and nonablative photorejuvenation in ethnic skin
Van Tran et al. Light emitting diodes technology-based photobiomodulation therapy (PBMT) for dermatology and aesthetics: Recent applications, challenges, and perspectives
Bjerring Photorejuvenation–an overview
Bjerring et al. Skin fluorescence controlled photodynamic photorejuvenation (wrinkle reduction)
CN111001093A (zh) 一种低频超快激光色斑治疗装置
Khamees et al. The use of lasers (ablative laser, non-ablative laser, fractional laser, photobiomodulation (PBM)) in skin regeneration
Stangl et al. Side effects and complications using intense pulsed light (IPL) sources
Cannarozzo et al. Atlas of lasers and lights in dermatology
Small A practical guide to laser procedures
CN212016471U (zh) 一种低频超快激光色斑治疗装置
Harsh et al. Facial laser surgery
Gold Light-emitting diode
WO2009128570A1 (fr) Traitement de la rosacée érythémato-télangiectasique ou de la rosacée papulopustulaire avec un rayonnement de lumière infrarouge à bande étroite et kits de rayonnement pour ledit traitement
Fedok et al. Cutaneous lasers
Green et al. Low-Level Light Therapy with LEDs
Haney Laser and Light-Based Treatments
Mohamed et al. Efficacy and Safety of 577‐nm Yellow Laser in the Treatment of Pigmented Epidermal Lesions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07834072

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2707074

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007361011

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007361011

Country of ref document: AU

Date of ref document: 20071116

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 2010002270

Country of ref document: MY

122 Ep: pct application non-entry in european phase

Ref document number: 07834072

Country of ref document: EP

Kind code of ref document: A1